경구 단백질 및 펩티드 시장 : 제품 유형별, 제제별, 환자 유형별, 용도별, 최종 사용자별, 유통 채널별 시장 예측(2026-2032년)

The Oral Proteins & Peptides Market is projected to grow by USD 18.66 billion at a CAGR of 13.29% by 2032.

The oral proteins and peptides market is moving from a long-standing formulation challenge into a strategic pharmaceutical growth arena. Protein and peptide therapeutics such as GLP-1 receptor agonists, insulin candidates, parathyroid hormone analogs, calcitonin, and somatostatin analogs have historically relied on injections because gastrointestinal enzymes, mucus barriers, and epithelial tight junctions restrict oral bioavailability.

Commercial progress has validated the category. The U.S. FDA approved oral semaglutide in 2019 as the first oral GLP-1 receptor agonist, and oral octreotide capsules were approved in 2020 for acromegaly maintenance therapy. These milestones support growing investment in permeation enhancers, enzyme inhibitors, enteric coatings, nanoparticles, mucoadhesive systems, and device-enabled capsules designed to improve absorption while preserving peptide stability.

Transformative Shifts in the Oral Peptide Delivery Landscape

The most important shift is the movement from proof-of-concept oral delivery toward differentiated product life-cycle strategies. Pharmaceutical developers are using oral peptide programs to improve patient adherence, extend therapeutic options, reduce injection burden, and compete in chronic diseases where convenience directly affects persistence.

Demand is being reinforced by the global burden of metabolic disease. The International Diabetes Federation estimated that 537 million adults were living with diabetes in 2021, while the World Health Organization reported that more than 1 billion people were living with obesity in 2022. These epidemiological realities make oral GLP-1 therapies, oral insulin approaches, and other peptide-based therapies high-priority targets for clinical development and commercialization.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating oral protein and peptide development by improving peptide design, excipient selection, stability prediction, and formulation screening. Machine learning models can evaluate relationships among molecular weight, charge, hydrophobicity, proteolytic susceptibility, permeability, and release kinetics, reducing the number of laboratory iterations required to identify promising candidates.

AI is also influencing clinical and commercial execution. Predictive analytics support patient stratification, dose optimization, adherence modeling, pharmacovigilance signal detection, and manufacturing process control. As regulatory agencies increasingly accept model-informed drug development when supported by robust evidence, AI-enabled workflows are becoming a competitive advantage rather than a peripheral research tool.

Key Regional Insights Across Global Markets

North America remains a leading region because of its concentration of biotechnology capabilities, advanced clinical trial infrastructure, strong payer engagement, and FDA experience with oral peptide approvals. The United States anchors demand through high diabetes and obesity prevalence, while Canada contributes through publicly supported research networks and an increasingly sophisticated specialty pharmaceutical environment.

Europe benefits from established regulatory pathways through the European Medicines Agency, strong biologics manufacturing capabilities, and active peptide research across Germany, France, Italy, Spain, and the United Kingdom. Asia-Pacific is gaining momentum as China, India, Japan, South Korea, and Australia expand clinical development capacity, contract manufacturing, and demand for chronic disease therapies. Latin America, led by Brazil and Mexico, shows rising access potential as metabolic disorders increase and private specialty channels develop, while the Middle East is shaped by high diabetes burden and healthcare modernization across Gulf health systems. Africa remains earlier in adoption but is increasingly relevant as urbanization, noncommunicable disease strategies, and medicine access initiatives expand across major economies.

Key Group Insights for Strategic Market Prioritization

ASEAN countries are becoming important for oral peptide market expansion as healthcare coverage improves and regional manufacturers strengthen formulation, packaging, and distribution capabilities. Singapore and Malaysia offer clinical and regulatory sophistication, while Indonesia, Thailand, Vietnam, and the Philippines provide sizable patient populations for diabetes and cardiometabolic therapies.

The GCC is increasingly relevant due to national diabetes management programs, specialty care investment, and healthcare transformation initiatives across Gulf economies. The European Union supports harmonized regulatory review, pharmacovigilance, and high-quality manufacturing standards that are important for complex oral biologics. BRICS countries offer scale, domestic manufacturing priorities, and rising demand for chronic disease treatment, particularly in China, India, and Brazil. G7 markets continue to lead premium innovation, clinical evidence generation, and reimbursement discussions, while NATO countries overlap heavily with advanced North American and European markets, supporting resilient supply chains, stringent quality expectations, and coordinated regulatory standards.

Key Country Insights for Oral Proteins and Peptides

The United States is the most influential country market due to FDA precedent, high specialty drug utilization, and a large population affected by obesity and diabetes. Canada offers stable market access pathways and research collaborations, while Mexico and Brazil provide important Latin American demand opportunities as private healthcare, specialist prescribing, and specialty pharmacy channels expand.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine clinical research depth with advanced reimbursement systems, while Russia remains a differentiated market shaped by localization requirements, regulatory complexity, and access constraints. China and India are central to future scale because of large patient populations, active domestic pharmaceutical investment, expanding clinical trial activity, and policy focus on local production. Japan and South Korea contribute advanced drug delivery research, strong quality systems, and high adoption of innovative therapies, while Australia serves as a credible clinical development and early market access environment supported by recognized regulatory standards and research infrastructure.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize candidates where oral delivery provides measurable clinical and commercial value, including chronic diseases requiring long-term adherence. Programs should demonstrate not only bioavailability but also durable efficacy, acceptable food-effect management, gastrointestinal tolerability, and clear patient preference versus injectable alternatives.

Organizations should invest in platform technologies, AI-enabled formulation screening, scalable manufacturing, and early regulatory engagement. Commercial teams should prepare evidence packages for payers that quantify adherence, persistence, total cost of care, and quality-of-life benefits. Partnerships with contract development and manufacturing organizations, academic laboratories, and digital adherence providers can reduce development risk and accelerate launch readiness.

Research Methodology

This executive summary is developed using a structured secondary research methodology aligned with established market intelligence standards. Inputs include regulatory approval records, public agency publications, peer-reviewed literature, clinical trial registries, patent activity, and recognized epidemiological sources such as the International Diabetes Federation and the World Health Organization.

The analysis triangulates technology trends, therapeutic demand, regional healthcare infrastructure, regulatory maturity, and commercialization dynamics. Insights are validated through consistency checks across multiple sources and are presented without unsupported market sizing, market share claims, or speculative forecasting.

Conclusion

Oral proteins and peptides are positioned to reshape biologic therapy by combining the potency of peptide drugs with the convenience of oral administration. The market is supported by proven regulatory milestones, expanding metabolic disease demand, and rapid advances in formulation science.

The strongest performers will be organizations that integrate drug delivery innovation, AI-driven development, clinical differentiation, scalable manufacturing, and payer-relevant outcomes. As oral peptide platforms mature, they can improve adherence, expand access, and create new competitive benchmarks across chronic and specialty care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Oral Proteins & Peptides Market, by Product Type

• 7.1. Insulin-Based Proteins
  • 7.1.1. Combination Insulin Products
  • 7.1.2. Long-Acting Insulin Analogues
  • 7.1.3. Rapid-Acting Insulin Analogues
  • 7.1.4. Recombinant Human Insulin
• 7.2. Peptide Therapeutics
  • 7.2.1. Calcitonin-Based Therapies
  • 7.2.2. Glucagon-Like Peptide-1 Receptor Agonists
  • 7.2.3. Vasopressin Analogs

8. Oral Proteins & Peptides Market, by Formulation

• 8.1. Capsule Formulations
• 8.2. Liquid Formulations
• 8.3. Powder Formulations
• 8.4. Tablet Formulations

9. Oral Proteins & Peptides Market, by Patient Type

• 9.1. Pediatric
• 9.2. Adult
• 9.3. Geriatric

10. Oral Proteins & Peptides Market, by Application

• 10.1. Cancer Treatment
• 10.2. Cardiovascular Diseases
• 10.3. Diabetes Management
• 10.4. Hormonal Disorders

11. Oral Proteins & Peptides Market, by End-User

• 11.1. Home Care Settings
• 11.2. Hospitals & Clinics
• 11.3. Research Laboratories
• 11.4. Specialty Clinics

12. Oral Proteins & Peptides Market, by Distribution Channel

• 12.1. Offline
• 12.2. Online

13. Oral Proteins & Peptides Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Oral Proteins & Peptides Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Oral Proteins & Peptides Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. AbbVie Inc.
• 17.2. Amgen Inc.
• 17.3. Amryt Pharma plc
• 17.4. Astellas Pharma Inc.
• 17.5. AstraZeneca PLC
• 17.6. Biocon Limited
• 17.7. Boehringer Ingelheim International GmbH
• 17.8. Catalent, Inc.
• 17.9. Entera Bio Ltd. by DNA Biomedical Solutions
• 17.10. F. Hoffmann-La Roche AG
• 17.11. Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital
• 17.12. Johnson & Johnson Services, Inc.
• 17.13. Merck KGaA
• 17.14. Novartis AG
• 17.15. Novo Nordisk A/S
• 17.16. Oramed Pharmaceuticals Inc.
• 17.17. PeptiDream Inc.
• 17.18. Pfizer, Inc.
• 17.19. Protagonist Therapeutics, Inc.
• 17.20. Proxima Concepts Limited
• 17.21. Rani Therapeutics, LLC
• 17.22. Sanofi S.A.
• 17.23. Tarsa Therapeutics, Inc.
• 17.24. Teva Pharmaceutical Industries Ltd.
• 17.25. Zealand Pharma A/S